Avrobio Inc   (AVRO)
Other Ticker:  
Price: $1.2200 $-0.02 -1.613%
Day's High: $1.29 Week Perf: -3.94 %
Day's Low: $ 1.22 30 Day Perf: -19.74 %
Volume (M): 68 52 Wk High: $ 1.93
Volume (M$): $ 83 52 Wk Avg: $1.21
Open: $1.26 52 Wk Low: $0.57

 Market Capitalization (Millions $) 54
 Shares Outstanding (Millions) 45
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) -84
 Capital Exp. (TTM) (Millions $) 0

Avrobio Inc

   Company Address: 100 Technology Square Cambridge 2139 MA
   Company Phone Number: 914-8420   Stock Exchange / Ticker: NASDAQ AVRO
   AVRO is expected to report next financial results on March 22, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Semper Paratus Acquisition Corporation

The arising business from the Biotechnology and Pharmaceuticals market the LGST published the fiscal third quarter of 2023, numbers

The Biotechnology and Pharmaceuticals sector experts continue to interpret the third quarter of 2023 earnings. Presently those experts observe operating deficit of $-0.605971 million, from the Semper Paratus Acquisition Corporation, which has not cited any top-line so far, for the own July to September 30 2023 quarter.

Ladrx Corporation

Ladrx Corporation's Fiscal Report Reveals Operating Shortfall of $-0.840313 Million in Biotechnology and Pharmaceuticals Sector for September 2023

The stock market is an ever-evolving landscape, filled with opportunities for both investors and corporations alike. In the Biotechnology and Pharmaceuticals sector, some companies often go unnoticed, but they are now emerging with promising earnings. One such corporation is Ladrx Corporation, which recently reported a decrease in its operating shortfall for the third quarter of 2023.
In comparison to the third quarter of 2022, Ladrx Corporation's operating shortfall has significantly improved. Last year, the company experienced an operating shortfall of $-1.167527 million. However, this year, the shortfall has decreased to $-0.840313 million. These numbers serve as crucial signals for the state of Ladrx Corporation, indicating a positive trend in the company's financial performance.

Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics Inc's Trailblazing Journey: Overcoming a Surprising $-0.04 per Share Loss Amidst the Fiscal Time-frame Ending September 30, 2023

For the fiscal time-frame ending September 30 2023 LCTX lost money of $-0.04 per share compare to $-0.04 a year before and surged loss from $-0.03 per share from the previous quarter. The revenue fell sharply by -58.439 % to $1.25 million from $3.00 million in the comparable quarter a year before and sequentially Revenue Tumbled by -61.364 % from $3.23 million.

Bio Techne Corp

Reduction in Earnings while revenue grew in the July to September 30 2023 fiscal time-frame

Revenue improvement of 2.447 %, could not prevent income decline of -85.97 % in the most recent fiscal period, relative to comparable reporting period a year before. revenue were at $276.19 million and eps at $0.31.

Anavex Life Sciences Corp

Anavex Life Sciences Corp's EPS Soars by 454.76% Despite Decline in Revenue during Q4 2023

Date: November 30, 2023
Anavex Life Sciences Corp, a renowned Biotechnology and Pharmaceuticals company, recently reported its financial results for the fiscal fourth quarter of 2023. Despite a sharp decline in revenue, the company's earnings per share (EPS) witnessed a commendable surge. Let's delve into the details of these results and analyze what this means for the future of the company.
In the fiscal fourth quarter of 2023, Anavex Life Sciences Corp reported a staggering EPS growth of 454.76%. The EPS rose to $0.48 per share, compared to $0.09 per share in the same quarter a year ago. Moreover, the company was able to turn its EPS positive, bouncing back from a loss of $-0.14 per share in the prior quarter. This robust growth in earnings is undoubtedly a positive sign for shareholders and investors.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com